Skip to main content
. 2021 Dec 15;17(12):e1010083. doi: 10.1371/journal.ppat.1010083

Table 1. Recombinant adenoviruses used in this study.

Virus Short Replication FK IV/ml Reference
MAdV-1-IX-2A-GFP M1-IX-G Competent M1 2.7 x 106 b This study
MAdV-1-ΔE1A-GFP M1-ΔE1A-G Competent M1 1.0 x 107 b This study
MAdV-2-ΔE1A-GFP M2-ΔE1A-G Competent M2 4.4 x 107 b This study
MAdV-3-IX-2A-GFP M3-IX-G Competent M3 1.0 x 107 b This study
MAdV-3-ΔE1A-GFP M3-ΔE1A-G Competent M3 0.43 x 107 b This study
HAdV-C5-ΔE3B-CMV-GFP-FK-M1 H5-ΔE3B-CG-FK-M1 Competent M1 6.8 x 108 c This study
HAdV-C5-ΔE3B-CMV-GFP-FK-M3 H5-ΔE3B-CG-FK-M3 Competent M3 1.0 x 108 c This study
HAdV-C5-ΔE3B-CMV-GFP H5-ΔE3B-CG Competent H5 8.0 x 1010 c This study
HAdV-C5-ΔE1-CMV-GFP H5-ΔE1-CG Defective H5 1.1 x 1010 c [65]
HAdV-B3-ΔE1-CMV-GFP H3-ΔE1-CG Defective H3 4.0 x 109 c [66]
HAdV-B35-ΔE1-CMV-GFP-E4orf6-HAdV-C5 H35-ΔE1-CG Defective H35 1.0 x 109 c This study

a IV, infectious virus

b Titer was determined by GFP IFU assay, infecting CMT-93 cells.

c Titer was determined by plaque assay, infecting 911 cells.